Business
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP announces that a class action lawsui...
About this update from Bolt Metals Corp.
[{"type":"text","content":"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLTNEW YORK, NY / ACCESSWIRE / August 28, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (\"Bolt\" or the \"Company\") (NASDAQ:BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the \"Class Period\"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the \"Exchange Act\") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.If you are a shareholder who purchased or otherwise acquired Bolt securities during the Class Period, you have until September 3, 2024 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.[Click here for information about joining the class action]Bolt, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The Company's business model relies primarily on the success of its \"Boltbody\" pipeline of immuno-oncology product candidates. Bolt's product pipeline includes the immune-stimulating antibody conjugate (\"ISAC\") BDC-1001 , designed to target a tumor antigen known as human epidermal growth factor receptor 2 (\"HER2\") that is often found in cancers such as breast and gastroesophageal cancer, as well as BDC-3042 and BDC-4182, programs \"targeting the clinically validated cancer antigen Claudin 18.2.\"Historically, Bolt's lead asset was BDC-1001, which had pre-defined success criteria that included an overall...